Natural killer (NK) cells can kill a wide range of cancer cells and are a promising tool for cell therapy of cancer. NK cells cytotoxicity is regulated by a balance between stimulatory and inhibitory signals. Interleukin-2 is known to increase NK cell cytotoxicity. Although many cytokines have been studied in efforts to induce durable NK cell expansions, most reports indicate a rather modest effect and the requirement for additional stimuli. We found that contact with the K562 myeloid leukemia cell line, genetically modified to express a membrane-bound form of interleukin-15 and the ligand for the costimulatory molecule 4-1BB, induced vigorous expansion of NK cells from peripheral blood. Based on these findings, we developed a method for large-scale clinical-grade expansion of NK cells. This method is currently used to expand allogeneic NK cells for infusion in patients with leukemia and solid tumors. We here summarize methods for expansion and activation of NK cells from human peripheral blood mononuclear cells as well as clinical-scale methods to produce NK cells for immunotherapy under Current Good Manufacturing Practices (cGMP) conditions. ( Korean J Lab Med 2009; 29:89-96) 
INTRODUCTION
Duck Cho and Dario Campana sensitization, an effect that is regulated by the balance of stimulatory and inhibitory signals [4, 9, 10] . Many of the signaling receptors on the surface of NK cells engage major histocompatibility complex (MHC) class I and MHC class I-like molecules. A well-described mechanism is the inhibition of NK activity by increasing expression of MHC or human leukocyte antigen (HLA) class I in target cells [11] .
NK cells express killer immunoglobulin-like receptors (KIRs), most of which recognize specific corresponding HLA class I molecules on target cells, and deliver inhibitory signals [4, 9, 10] . These inhibitory signals from HLA can override activating signals and suppress the function of NK cells. A concept that has recently emerged is that interaction between NK cells and HLA molecules might also be important for their functional maturation and the generation of NK cells that are tolerant towards self molecules, a process which has been termed ' 'licensing' ' [12] . 
METHODS TO EXPAND NK CELLS

Cytokines and stimulants
Several protocols for NK-cell expansion have been reported (summarize in Table 1 ; see also www.nkcells.info/ wiki/index.php/NK_cell_expansion). Many cytokines have been studied in efforts to induce durable NK cell expansion as well as to increase their cytotoxicity [13] . Interleukin (IL)-2 can enhance the cytotoxicity of NK cells within 24 hr of incubation [14, 15] . IL-2 can also stimulate their proliferation but only a minority of NK cells can maintain proliferation after the initial response [14, 16, 17] . IL-4, IL-7 and IL-12 also induced some proliferative stimuli but are overall less potent than IL-2 [18] . Likewise, IL-15 alone or in combination with IL-2 typically results in minimal NK cell expansion [8] . We found that IL-2 (1,000 IU/mL) or IL-15 (10 ng/mL) did not induce significant expansion of NK cells [19] . It appears that cytokines may be necessary but not sufficient for optimal proliferation of NK cells.
Recently, Alici et al. [20] used culture conditions using IL-2 (500 IU/mL) with an anti-CD3 antibody (Orthoclone OKT-3, 10 ng/mL) and reported that the number of NK cells from the peripheral blood of 7 newly diagnosed, untreated patients with multiple myeloma had expanded on average 1,600-fold after 20 days of culture. This is in striking contrast with the 190-fold expansion obtained using NK cells from healthy individuals [21] 
Expansion of NK cells with accessory cells
Most investigators believe that sustained proliferations of NK cells require additional signals [23, 24] , such as the presence of monocytes [23] or B-lymphoblastoid cells [16, 25, 26] . Miller et al. [23] reported an approximate 30-fold expansion of NK cells after 18 days of culture with 1,000 IU/mL IL-2 and monocytes. Perussia et al. [27] found that contact with irradiated B-lymphoblastoid cells induced as high as a 25-fold expansion of NK cells after 2 weeks of stimulation. Harada et al. [28] reported that HFWT, a Wilms tumor-derived cell line, stimulates up to 400-fold NK expansion after 2 weeks. Other investigators have used allogeneic mononuclear cells [29] , autologous lymphocytes [30] , mitogen activated lymphocytes [25] , and umbilical cord mesenchymal cells [31] .
Contact with K562 cells, a cell line derived from a patient with myeloid blast crisis of chronic myelogenous leukemia and bearing the BCR-ABL1 translocation, is known to induce modest proliferations of NK cells [28, 32] , and augment NK cell proliferation in response to IL-15 [24] . We genetically modified K562 cells to express two NK stimulatory molecules. One, the ligand for 4-1BB (4-1BBL), induces activation signals through 4-1BB (CD137), a costimulatory molecule expressed on the surface of NK cells [33] .
The other, IL-15, is known to support NK-cell maturation and survival [34] [35] [36] [37] . IL-15 has greater activity when bound to the cell membrane of stimulatory cells, rather than in its soluble form [38] [39] [40] [41] [42] receptor [19] . Addition of 4-1BB was also associated with increased production of IFN-γand GM-CSF [19] .
CLINICAL LARGE-SCALE NK CELL ACTIVATION AND EXPANSION
Methodologic considerations
It is now feasible to obtain clinical-grade purified functional NK cells for infusion [44] . [43] . The expansion in these large-scale cultures was higher than that observed in small-scale experiments, most likely because of the use of SCGM tissue culture medium instead of RPMI-1640 (SCGM appears to be well suited to support NK cell growth) [20] . We therefore estimate that it would be feasible to obtain the num- 
Therapeutic applications of NK cells
In the setting of hematopoietic stem-cell transplantation, donor NK cells may exert an anti-leukemia effect if they do not express KIRs reacting with the HLA class I epitope expressed by the patient' s leukemia cells. In animal mod- ative disease and lymphoma [55] . Other EBV-associated tumors may also be amenable to this form of therapy [56, 57] . However, most cancers lack identifiable virus-associated antigens [58] , although other molecules, such as WT1
and Pr3, are overexpressed in some cancer cells and are possible targets for adoptive T-cell therapy [59, 60] . [59, 60] and malignant glioma [59] . Second, they can be used in an allogeneic setting without the risk of graft-versus-host disease [44] .
Thirdly, with the method described in this review, large numbers of cytotoxic NK cells can be reliably obtained in a relatively short period of time.
For malignancies that are relatively resistant to NK cells, strategies that can be explored include genetic modification with artificial receptors, such as the one that we reported using anti-CD19 receptors for the treatment of B-cell neoplasias [19] . To this end, the overall strategy that we have described is not limited to CD19 + leukemia and lymphoma cells but is also applicable to many other molecules expressed by cancer cells and can be implemented by replacing the anti-CDc19 scFv with the scFv of another antibody [61, 62] .
